1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Infections
  5. Antimicrobial stewardship

COVID-19 rapid guideline: managing COVID-19

NICE guideline [NG191] Published: 23 March 2021 Last updated: 08 May 2024

  • Guidance
  • Tools and resources
  • Evidence
  • History
Download (PDF)

Evidence reviews to support NHS England commissioning policies

These evidence reviews were developed to support the following NHS England commissioning policies.  NICE has conducted a more recent review of the evidence for its rapid guideline.
 
NHSE commissioning policies
  • Interim Clinical Commissioning Policy: Remdesivir for patients hospitalised with COVID-19 (adults and children 12 years and older)
  • Interim Clinical Commissioning Policy: Tocilizumab for hospitalised patients with COVID-19 pneumonia (adults)

  • Interim Clinical Commissioning Policy: Sarilumab for critically ill patients with COVID-19 pneumonia (adults). 

Download the associated evidence reviews:

  • ES27 Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 
  • ES33 Tocilizumab for COVID-19
  • ES34 Sarilumab for COVID-19.

This page was last updated: 23 March 2021